Mochida Pharmaceutical Co
Mochida Pharmaceutical Co., Ltd., commonly referred to as Mochida, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1949, the company has made significant strides in developing innovative healthcare solutions, particularly in the fields of anaesthetics, anti-infectives, and other therapeutic areas. With a strong presence in both domestic and international markets, Mochida is dedicated to advancing medical science through its core products, which are distinguished by their quality and efficacy. The company has achieved notable milestones, including the development of unique formulations that cater to specific patient needs. Recognised for its commitment to research and development, Mochida Pharmaceutical continues to solidify its market position, contributing to global health advancements while maintaining a focus on patient-centric solutions.
DitchCarbon Score
How does Mochida Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mochida Pharmaceutical Co's score of 33 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mochida Pharmaceutical Co's reported carbon emissions
In 2023, Mochida Pharmaceutical Co reported total carbon emissions of approximately 13,018,000 kg CO2e, comprising 4,017,000 kg CO2e from Scope 1 and 9,311,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions for this year. Over the years, Mochida has shown a trend of decreasing emissions. For instance, in 2022, total emissions were about 16,685,000 kg CO2e, with Scope 1 and Scope 2 emissions at 4,313,000 kg CO2e and 10,431,000 kg CO2e, respectively. This indicates a commitment to reducing their carbon footprint, although specific reduction targets or initiatives have not been outlined. Mochida Pharmaceutical Co has not set any formal reduction targets or climate pledges, which may limit their ability to align with industry standards for climate action. The absence of Science-Based Targets Initiative (SBTi) commitments suggests a potential area for improvement in their climate strategy. Overall, while the company has made strides in reducing emissions, further transparency and commitment to specific reduction goals would enhance their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 19,606,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 370,000 | 000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | 19,606,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 0,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mochida Pharmaceutical Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
